GHRH Analog
FDA-Studied Visceral Fat Reduction
Tesamorelin is a synthetic GHRH analog specifically targeting visceral adipose tissue—the harmful deep belly fat linked to metabolic disease. FDA-studied for reducing abdominal fat accumulation, Tesamorelin offers precise metabolic benefits through natural growth hormone pathways.
15%
VAT Reduction*
FDA
Studied
44
Amino Acids
22+
BHRC Locations
Available Option
A synthetic analog of human growth hormone-releasing hormone designed to specifically target visceral adipose tissue reduction through natural GHRH receptor activation.
Tesamorelin 10mg per vial
Ideal For
Patients seeking targeted reduction of visceral abdominal fat, metabolic health optimization, and body composition improvements with FDA-studied efficacy.
The Science
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), consisting of 44 amino acids with enhanced stability. It binds to GHRH receptors in the pituitary gland to stimulate natural growth hormone production—but with a unique focus on visceral fat metabolism.
Unlike direct growth hormone administration, Tesamorelin works through your body’s own regulatory pathways, maintaining physiologic GH pulsatility. Clinical trials demonstrated an average 15% reduction in visceral adipose tissue (VAT) after 26 weeks of treatment—the dangerous deep abdominal fat associated with cardiovascular disease, insulin resistance, and metabolic syndrome.
Originally FDA-approved for lipodystrophy in HIV patients, Tesamorelin is now used in broader metabolic optimization protocols. At BHRC, our physicians leverage its targeted mechanism for patients struggling with abdominal adiposity despite diet and exercise efforts.
Book a Consultation
How It Works
Tesamorelin activates natural GHRH receptors to stimulate pulsatile growth hormone release, which specifically enhances lipolysis in visceral adipose tissue while maintaining metabolic balance.
Binds to pituitary GHRH receptors with high affinity, triggering the natural cascade of growth hormone synthesis and secretion through physiologic pathways.
Stimulates pulsatile GH secretion that mimics natural patterns, increasing serum growth hormone and subsequently IGF-1 levels in a controlled manner.
Enhanced GH/IGF-1 axis selectively promotes lipolysis in visceral adipose tissue—reducing dangerous abdominal fat that surrounds internal organs.
Clinical Benefits
Clinical trials demonstrated up to 15% reduction in visceral adipose tissue—targeting the dangerous deep abdominal fat linked to cardiovascular disease and metabolic syndrome.
Reducing visceral fat improves insulin sensitivity, glucose metabolism, and lipid profiles—addressing key markers of metabolic health and disease risk.
Supports lean muscle preservation while specifically targeting abdominal fat, improving waist-to-hip ratio and overall body composition without generalized weight loss.
Visceral fat reduction correlates with decreased cardiovascular risk markers, improved arterial function, and reduced inflammatory cytokines associated with heart disease.
Backed by rigorous clinical trials and FDA approval for lipodystrophy, Tesamorelin has a well-documented safety profile and proven efficacy in targeting visceral fat.
Works through your body’s own GHRH receptors to stimulate physiologic growth hormone release—avoiding the risks of direct GH administration.
Your Journey
Our medical team guides you through every step—from initial consultation to ongoing optimization.
Meet with our physician to assess your visceral adiposity, metabolic health, and determine if Tesamorelin is right for you.
Comprehensive metabolic panel including IGF-1, glucose, lipids, and liver function to establish baseline health markers.
Personalized treatment plan with precise dosing, injection training, and lifestyle recommendations to maximize visceral fat reduction.
Regular follow-ups with imaging assessments, lab monitoring, and protocol adjustments to ensure safe, effective results.
Safety & Candidacy
Tesamorelin underwent rigorous clinical trials leading to FDA approval for reducing excess abdominal fat in HIV patients with lipodystrophy. This extensive research provides strong safety and efficacy data for visceral fat reduction.
26wks
Typical treatment duration in pivotal trials showing significant VAT reduction
1x/day
Once-daily subcutaneous injection, typically administered before bedtime
Questions
Tesamorelin is unique in its FDA-studied, specific action on visceral adipose tissue—the dangerous deep abdominal fat. Unlike general fat loss compounds, it targets the metabolically harmful fat surrounding organs, with clinical trials demonstrating average 15% VAT reduction. It’s a GHRH analog working through natural pathways rather than direct GH administration.
Tesamorelin is administered via once-daily subcutaneous injection, typically before bedtime to align with natural GH secretion patterns. Our clinical team provides comprehensive training on proper reconstitution, injection technique, injection site rotation, and storage during your initial consultation.
Visceral adipose tissue (VAT) is the deep abdominal fat that surrounds internal organs like the liver, pancreas, and intestines. Unlike subcutaneous fat (under the skin), VAT is metabolically active and strongly associated with insulin resistance, cardiovascular disease, inflammation, and increased mortality risk. Reducing VAT improves metabolic health markers even without significant weight loss.
Clinical trials demonstrated significant visceral fat reduction after 26 weeks of treatment. Many patients notice improvements in abdominal circumference and metabolic markers within 8-12 weeks, with optimal results developing over 6 months. Body composition imaging (DEXA or CT) at baseline and follow-up objectively quantifies VAT reduction.
The most common side effects are mild injection site reactions, arthralgia (joint discomfort), and peripheral edema. Some patients experience transient increases in blood glucose, requiring monitoring especially in those with diabetes or prediabetes. Most side effects are mild and resolve with continued use or dose adjustment under physician guidance.
Ideal candidates are adults with excess visceral abdominal fat despite diet and exercise efforts, those with metabolic syndrome markers, or individuals seeking targeted reduction of deep belly fat. Contraindications include active malignancy, pregnancy, disruption of the hypothalamic-pituitary axis, or hypersensitivity to Tesamorelin. A physician consultation with imaging and lab work is required.
Treatment monitoring includes regular clinical assessments, metabolic panels (glucose, HbA1c, lipids), IGF-1 levels, liver function tests, and body composition analysis. Imaging such as DEXA or CT scans quantifies visceral fat reduction. Your physician will schedule follow-ups at 4-8 week intervals initially, then quarterly for ongoing optimization and safety monitoring.
Get Started
Schedule a consultation with our medical team to learn if Tesamorelin peptide therapy is right for your metabolic health and body composition goals.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration beyond the approved indication. Tesamorelin is FDA-approved for reducing excess abdominal fat in HIV patients with lipodystrophy. Use for other indications is off-label and administered under medical supervision. The 15% VAT reduction data is from clinical trials. Individual results may vary. Tesamorelin may affect glucose metabolism and is contraindicated in patients with active malignancy or certain pituitary conditions. A consultation with our medical team and comprehensive laboratory testing including imaging assessment are required to determine if this therapy is appropriate for you.
